In vitro schedule-dependent interaction between paclitaxel and vinorelbine in A2780 parental and multidrug-resistant human ovarian cancer cell lines

International Journal of Oncology

Volumn 11, Issue 6, 1997, Pages 1379-1385

  Roch, Isabelle ^a,b   Bressolle, Francoise ^a,b   Pinguet, Frederic ^a  

^a Anticancer Center   (France)

^b UNIV MONTPELLIER   (France)

Author keywords

Multidrug resistance; Ovarian cancer; Paclitaxel; Vinorelbine

Indexed keywords

NAVELBINE; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CANCER INHIBITION; CLINICAL PROTOCOL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG POTENTIATION; HUMAN; HUMAN CELL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL;

EID: 0030776016     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.11.6.1379     Document Type: Article

References (5)

1. Ozols RF: The case for combination chemotherapy in the treatment of advanced ovarian cancer. J Clin Oncol 3: 1445-1447, 1985.
2. Wani MC, Taylor HL, Wall ME, Coggen P and McPhail AT: Plant antitumor agents VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent fron Taxus brevifolia. J Am Chem Soc 93: 2325, 1971.
3. Schiff PB, Fant J and Horwitz SB: Promotion of microtubule assembly in vitro by paclitaxel. Nature 277: 665-667, 1979.
4. Schiff PB and Horwitz SB: Paclitaxel stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77: 1561-1565, 1980.
5. Einzig AI, Wiernick PH, Sasloff J, Runowicz CD and Goldberg GL: Phase II study and long-term follow-up of patients treated with paclitaxel for advanced ovarian adenocarcinoma. J Clin Oncol 10: 1748-1753, 1992.